title: Influence of adenosinergic drugs on ethanol withdrawal syndrome in rats.
abstract: The influence of adenosine, its analogs: (-)N6-(R-phenylisopropyl)-adenosine (R-PIA), N6-cyclohexyladenosine (CHA), 5-(N-ethylcarboxamido)-adenosine (NECA), adenosine uptake inhibitor-dipyridamole, and theophylline and caffeine (adenosine receptor antagonists) on ethanol withdrawal syndrome was investigated in rats. Adenosine (100 mg/kg ip), all adenosine analogs and dipyridamole (30 mg/kg ip) reduced the number of rats in which audiogenic convulsions appeared. Caffeine and theophylline (5-25 mg/kg ip) did not influence significantly the audiogenic seizures, but they antagonized the depressing effects of adenosine analogs on these withdrawal symptoms. The results suggest that adenosine mechanisms in the brain may be implicated in the development of ethanol withdrawal syndrome.
authors.affiliation: Department of Pharmacodynamics, Medical Academy, Lublin, Poland.
authors.forename: D
authors.initials: D
authors.lastname: Malec
authors.forename: E
authors.initials: E
authors.lastname: Michalska
authors.forename: J
authors.initials: J
authors.lastname: Pikulicka
mesh_terms: D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D019830:Adenosine-5'-(N-ethylcarboxamide); D000818:Animals; D002110:Caffeine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D002492:Central Nervous System Depressants / Q000633:toxicity*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004176:Dipyridamole / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D000431:Ethanol / Q000633:toxicity*; D010660:Phenylisopropyladenosine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D051381:Rats; D018047:Receptors, Purinergic P1 / Q000187:drug effects*; D012640:Seizures / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D013806:Theophylline / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D002492:Central Nervous System Depressants; D000697:Central Nervous System Stimulants; D058906:Purinergic P1 Receptor Agonists; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; D014665:Vasodilator Agents; D010660:Phenylisopropyladenosine; D019830:Adenosine-5'-(N-ethylcarboxamide); C027513:N(6)-cyclohexyladenosine; D002110:Caffeine; D000431:Ethanol; D004176:Dipyridamole; D013806:Theophylline; D000241:Adenosine